 Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: The dynamic changes of tumor-infiltrating immune cells can predict the patient's response to neoadjuvant chemotherapy

J Immunother Cancer: The dynamic changes of tumor-infiltrating immune cells can predict the patient's response to neoadjuvant chemotherapy

 Last Update: 2021-05-20
 Source: Internet
 Author: User

Tags

immune reaction

ln 0 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Triple negative breast cancer (TNBC) is a heterogeneous tumor with a poor prognosis.

Breast cancer.

This study performed immunohistochemical analysis of matched tumor biopsy samples from 66 TNBC patients from the WSG-ADAPT-TN trial at baseline and 3 weeks after NACT treatment.

The levels of CD4, CD8, CD73, T cells, PD1-positive CD4 and CD8 cells and PDL1 in the stroma and/or tumor at baseline and at the 3rd week were assessed, and the correlation between changes in these indicators and pCR

Note: "cold": lack of immune cell infiltration; "hot" tumor cells are in contact with immune cells.

PD1-positive CD4 and PD1-positive CD8 cells infiltrate tumors with a higher pCR rate after the transition from "cold" to "hot" PD1-positive CD8 cells are converted from "hot" to "cold" pCR T cells and PD1-positive CD4 are not observed The pCR rate of tumors whose cell infiltration changes from "hot" to "cold" is significantly reduced

In conclusion, this exploratory study suggests that the comprehensive analysis of early immune cell infiltration dynamics supplements the predictive markers of pCR and is expected to improve the adjustment of personalized treatment strategies for TNBC patients .

The comprehensive analysis of early immune cell infiltration kinetics supplements the predictive markers of pCR, which is expected to improve the adjustment of personalized treatment strategies for TNBC patients

Original source:

Graeser M, Feuerhake F, Gluz O, et al bmj.

bmj.
com/content/9/5/e002198" target="_blank" rel="noopener">Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.